TROP2 Antibody–Drug Conjugates in 2026: Competitive Landscape, Clinical Evidence, and Safety Challenges
Introduction
Trophoblast cell surface antigen 2 (TROP2) is a transmembrane glycoprotein broadly overexpressed across epithelial malignancies—including breast cancer, non-small cell lung cancer (NSCLC), and urothelial carcinoma—with comparatively limited expression in normal tissues. This differential expression profile has made TROP2 an attractive platform for antibody–drug conjugate (ADC) development. As of mid-2026, the field has progressed from a single approved agent to a multiagent landscape spanning diverse tumor types, regulatory jurisdictions, and ADC engineering strategies. This narrative review synthesizes the current competitive status, key clinical evidence, safety challenges, and future outlook for TROP2-directed ADCs, targeting oncologists, clinical researchers, and medical affairs professionals.
1. Competitive Landscape
Table 1. TROP2 ADC Competitive Landscape (as of June 2026)
| Agent (Synonyms) | Sponsor/Partner | ADC Platform/Payload | Development or Approval Status | Key Tumor Types | Notable Regulatory Regions |
|---|---|---|---|---|---|
| Sacituzumab govitecan (Trodelvy; SG; IMMU-132) | Immunomedics/Gilead; Everest Medicines (Greater China) | TROP2/SN-38 (hydrolyzable linker; TOP1 inhibitor) | FDA approved (TNBC; HR+/HER2− BC); urothelial indication withdrawn (Nov 2024); NMPA filing received | mTNBC; HR+/HER2− mBC | USA; EU major markets; NMPA (filing) 291 |
| Datopotamab deruxtecan (Datroway; Dato-DXd; DS-1062) | Daiichi Sankyo/AstraZeneca | TROP2/DXd (plasma-stable cleavable linker; DAR=4; TOP1 inhibitor) | FDA approved: HR+/HER2− BC (Jan 2025); EGFR-mut NSCLC accelerated (Jun 2025); TNBC (May 2026); EMA NSCLC application withdrawn (Dec 2024); BLA/NDA under review multiple regions | HR+/HER2− mBC; TNBC; EGFR-mut NSCLC | USA (3 approvals); EMA (NSCLC withdrawn); Japan; China (Phase III/BLA) 2425226 |
| Sacituzumab tirumotecan (SKB264; MK-2870; sac-TMT) | Sichuan Kelun Botai/Merck & Co. | TROP2/belotecan derivative (TOP1 inhibitor) | Phase III (OptiTROP-Breast01, OptiTROP-Lung04); NMPA Priority Review (Mar 2026, NSCLC); China/Japan approvals per dataset | mTNBC; EGFR-mut NSCLC; ovarian; gastric; endometrial | China; Japan; USA (TroFuse-009 ongoing); EU 272830 |
| DB-1305/BNT325 | BeiGene/Nanjing Luokang/BioNTech | TROP2/TOP1 inhibitor (cleavable linker) | Phase I/II (TNBC, NSCLC, ovarian, CRC) | TNBC; NSCLC; CRC; Ovarian | China; USA (investigational) 3123 |
| SHR-A1921 | Jiangsu Hengrui | TROP2/TOP1 inhibitor | Phase I–III (SCLC-R, CRC, ovarian) | Ovarian; SCLC-R; CRC | China; USA (preclinical) 23 |
| ESG-401 (OQY-3258) | Shanghai Escugen/Levena Biopharma | TROP2/TOP1 inhibitor | Phase II–III (breast, CRC); preclinical (bladder) | Breast; CRC; Bladder | China 23 |
| OBI-992 | Oncobin Biotechnology | TROP2/exatecan (novel epitope; hydrophilic linker) | Phase I/II (solid tumors) | Solid tumors (broad) | Investigational 17 |
The landscape is dominated by topoisomerase I (TOP1) inhibitor payloads across all clinically active agents. Payload class notwithstanding, linker stability, drug-to-antibody ratio (DAR), and antibody epitope create meaningful differentiation. China's regulatory momentum is notable: in March 2026 alone, 12 ADC programs—9 featuring TOP1 payloads—received expedited review pathway designations from the National Medical Products Administration (NMPA), underscoring the region's strategic investment in this class 30.
2. Clinical Evidence Across Major Tumor Types
Table 2. Key Clinical Trial Evidence for TROP2 ADCs (Phase II–III)
| Agent | Trial (Phase) | Indication/Line | Comparator | Median PFS (mo) | Median OS (mo) | ORR (%) | Key Safety Signals | Interpretation/Limitations |
|---|---|---|---|---|---|---|---|---|
| Dato-DXd | TROPION-Breast02 (III) | 1L TNBC, IO-ineligible | Investigator's choice chemo | 10.8 vs 5.6 (HR 0.57; p<0.0001) | 23.7 vs 18.7 (HR 0.79; p=0.029) | 64 vs 30 | ILD/pneumonitis 3%; stomatitis 63% (G≥3 8%); ocular AEs ~38% | First randomized OS-positive result in 1L IO-ineligible TNBC; open-label; distinct toxicity profile vs taxanes 2 |
| Dato-DXd | TROPION-Breast01 (III) | HR+/HER2− mBC, post 1–2 chemo lines | Investigator's choice chemo | 6.9 vs 4.9 (HR 0.63; p<0.0001) | 18.6 vs 18.3 (HR 1.01; NS) | 36 vs 23 | G≥3 TRAEs 20.8% vs 44.7%; stomatitis 50% (G≥3 6.4%); ILD 3.3% (1 fatal) | Significant PFS; OS not significant; favorable hematologic profile; OS follow-up ongoing 2519 |
| Dato-DXd | TROPION-Lung01 (III) | Previously treated advanced NSCLC (all histologies) | Docetaxel | 4.4 vs 3.7 (HR 0.75; p=0.004); nonsquamous: 5.5 vs 3.6 (HR 0.63) | 12.9 vs 11.8 (HR 0.94; NS); nonsquamous: 14.6 vs 12.3 (HR 0.84) | 26.4 vs 12.8 | ILD 8.8% (G≥3 4.4%; fatal 2.4%); stomatitis 55% (G≥3 6.7%); ocular 40% | Met PFS endpoint; OS NS overall; marked histology dependency (inferior in squamous, PFS HR 1.41); ILD vigilance essential 184 |
| Dato-DXd | TROPION-Lung05 (II) | EGFR-mut NSCLC (post TKI + platinum) | Single-arm | 5.4–5.8 (EGFR-mut) | 13.6 overall; 18.3 EGFR-mut | 35.8 overall; 43.6 EGFR-mut; pooled with Lung01: 45% (accelerated approval basis) | Stomatitis 56–66% (G≥3 9–11%); ILD 3.6% (1 fatal) | Activity after osimertinib and chemotherapy; basis for FDA accelerated approval Jun 2025 2420 |
| Sacituzumab govitecan | ASCENT (III) | mTNBC, ≥2 prior lines | Physician's choice chemo | 4.8 vs 1.7 | 11.8 vs 6.9 | ~35 vs ~5 | Neutropenia (G≥3 ~51%); diarrhea (G≥3 ~10%); febrile neutropenia | Landmark trial; established 2L+ mTNBC standard; myelosuppression/diarrhea are boxed-warning toxicities 8 |
| Sacituzumab govitecan | TROPiCS-02 (III) | HR+/HER2− mBC, post endocrine, CDK4/6i, taxane | Physician's choice chemo | 5.5 vs 4.0 (HR 0.66; p=0.0003) | 14.4 vs 11.2 (HR 0.789; p=0.020) | — | G≥3 neutropenia 51%; G≥3 diarrhea 9% | Significant PFS and OS in heavily pretreated setting; G-CSF and antidiarrheal support essential 91011 |
| Sacituzumab tirumotecan | OptiTROP-Breast01 (III) | TNBC, ≥2 prior lines | Chemotherapy | 5.7 vs 2.3 (HR 0.31; p<0.00001) | NR vs 9.4 (p=0.0005) | 43.8 vs 12.8 | G≥3 TRAEs 57.7% vs 56.6%; mucosal and hematologic events; no treatment-related deaths | 69% risk reduction in progression/death; TROP2-high subgroup PFS 8.3 vs 2.3 mo; comparable G≥3 rate to chemo 28 |
| Sacituzumab tirumotecan | OptiTROP-Lung04 (III) | EGFR-mut NSCLC, post TKI | Platinum-based chemo | 8.3 vs 4.3 (HR 0.49; p<0.0001) | NR vs 17.4 (HR 0.60; p=0.0006) | — | Mild-to-moderate hematologic and mucosal events; no treatment-related deaths or discontinuations | Compelling phase III OS benefit in this population; NMPA Priority Review granted Mar 2026 27 |
| DB-1305/BNT325 | Phase I/II (TNBC) | TNBC, pretreated (no prior SG) | Single-arm | 5.55 (95% CI 2.76–9.13) | — | 34.6 | G≥3 TRAEs 34.6%; anemia 11.5%; stomatitis 7.7% | Small cohort (n=26); 92.3% Asian; preliminary signal; no treatment-related deaths 31 |
Cross-trial comparison caution: Differences in patient populations, lines of therapy, comparator regimens, and endpoints preclude direct comparative efficacy claims. These summaries are descriptive only.
Highlights by Tumor Type
Breast cancer represents the most advanced domain for TROP2 ADCs. Dato-DXd achieved three distinct FDA approvals across HR+/HER2−, TNBC (IO-ineligible), and EGFR-mutated NSCLC indications between January 2025 and May 2026 24252. In 1L IO-ineligible TNBC, TROPION-Breast02 delivered the first randomized OS benefit over chemotherapy in this specific population (23.7 vs 18.7 months), representing a paradigm-shifting development. Sacituzumab govitecan remains the established standard in later-line TNBC (ASCENT) and heavily pretreated HR+/HER2− disease (TROPiCS-02). Sacituzumab tirumotecan demonstrated a striking 69% PFS risk reduction in OptiTROP-Breast01 and awaits regulatory decisions outside Asia.
NSCLC reveals agent differentiation. Dato-DXd achieved FDA accelerated approval in EGFR-mutated NSCLC (June 2025) based on a pooled 45% ORR 24, though the EMA NSCLC application was withdrawn in December 2024 due to insufficient efficacy evidence and ILD concerns 26. Sacituzumab tirumotecan's OptiTROP-Lung04 data—with a 40% OS reduction versus chemotherapy—may reshape the treatment paradigm in post-TKI EGFR-mutated NSCLC, pending broader regulatory review 27.
Urothelial and other solid tumors: Sacituzumab govitecan's US urothelial indication was withdrawn in November 2024 following post-marketing reassessment; historical TROPHY-U-01 data (ORR 27.7%) remain contextually informative but are not reflective of current US labeling 13. Early signals for Dato-DXd in ovarian cancer (ORR 42.9%) and endometrial carcinoma (ORR 27.5%) from TROPION-PanTumor03 warrant further controlled investigation 5.
3. Safety Challenges
Table 3. Safety Profile Comparison Across TROP2 ADCs
| Toxicity Category | Agents Most Associated | Approximate Clinical Relevance | Monitoring/Management Considerations | Remaining Uncertainties |
|---|---|---|---|---|
| Neutropenia/leukopenia | Sacituzumab govitecan (G≥3 ~51% in TROPiCS-02); sacituzumab tirumotecan (~32.3% G≥3) | Dose-limiting; febrile neutropenia risk; boxed warning for SG | CBC before each cycle; primary G-CSF in high-risk patients; dose holds/reductions for G≥3; UGT1A1*28 genotyping for SG | Risk stratification across diverse populations; cumulative hematologic effects 1012 |
| Diarrhea | Sacituzumab govitecan (boxed warning; G≥3 ~9%) | Class-defining SG toxicity; can be severe and dehydrating | Prompt loperamide; IV hydration; electrolyte replacement; dose adjustment per severity | Microbiome role; combination with immunotherapy risk amplification 812 |
| Stomatitis/oral mucositis | Dato-DXd (50–66% any-grade; G≥3 6–11%); sacituzumab tirumotecan; DB-1305 | Very common with Dato-DXd; dose modifications in 10–20%; rarely discontinuation-forcing | Prophylactic dexamethasone mouthwash 0.1 mg/mL QID prior to Cycle 1; oral hygiene; infusion cryotherapy; topical analgesia for G2–3; dose delay/reduction for G≥3 | Mechanistic basis (TROP2-mediated salivary uptake vs direct payload toxicity); optimal prophylaxis duration 21 |
| Ocular surface toxicity | Dato-DXd (dry eye ~21–40%; keratitis ~1–5% G≥3) | Mostly G1–2; rarely dose-limiting; can impair quality of life | Baseline ophthalmology exam; lubricant eye drops; avoid contact lenses; repeat exams every 3 cycles; corticosteroids for keratitis; dose modification if G≥2 23 | Predictors of severity; long-term corneal damage risk; rechallenge safety |
| ILD/pneumonitis | Dato-DXd (3.3% breast; 8.8% NSCLC; fatal cases reported) | Rare but potentially fatal; higher incidence in NSCLC (squamous subgroup highest); prescribing information warning | Baseline CT and pulmonary history; exclude active ILD; patient education on cough/dyspnea; immediate hold if suspected; corticosteroids for G≥2; permanent discontinuation for confirmed G>2 182 | Histology- and dose-dependent risk; real-world incidence vs trial populations; rechallenge criteria |
| Nausea/vomiting | Dato-DXd (~51% nausea, ~20% vomiting in TROPION-Breast01; mostly G1–2); SG (~55%/~20%) | Manageable; G≥3 uncommon with TROP2 ADCs | 5-HT3 receptor antagonist (5-HT3RA); consider NK1RA and olanzapine for high-risk profiles; extended prophylaxis if prolonged pattern; dietary modification 17 | Harmonization of emetogenic risk classifications across guidelines; prospective data specific to TROP2 ADCs |
| Anemia | Sacituzumab tirumotecan (G≥3 ~27.7%); DB-1305 (G≥3 11.5%) | Cumulative with repeated dosing; transfusion occasionally required | CBC monitoring; iron supplementation; transfusion if Hgb <7–8 g/dL; dose reduction if persistent G≥3 2831 | Mechanistic attribution (payload vs antibody); biomarkers of risk |
Stomatitis Prophylaxis: Emerging Evidence
Across TROP2 ADC trials with Dato-DXd, stomatitis rates declined from 70–90% in early TROPION-PanTumor01 cohorts to 50–66% in later phase III studies, directly attributable to the implementation of prophylactic oral care protocols 21. The proposed mechanism involves TROP2 expression on salivary gland epithelium, leading to localized DXd payload uptake. Evidence from mTOR inhibitor trials (SWISH study) supports dexamethasone mouthwash efficacy: a 61% reduction in any-grade stomatitis and a 91% reduction in G≥2 events relative to historical controls. Meta-analytic evidence further supports oral cryotherapy during infusion (risk ratio 0.66; 95% CI 0.58–0.75) 21.
4. Differentiation and Positioning
ADC design fundamentally shapes clinical utility. Sacituzumab govitecan's hydrolyzable linker generates relatively higher systemic SN-38 exposure, driving robust antitumor activity alongside higher rates of neutropenia and diarrhea. Dato-DXd's plasma-stable, tumor-selective cleavable linker and lower DAR (4 vs ~7.6 for SG) correlate with markedly lower G≥3 hematologic toxicity compared with standard chemotherapy, but trade this for higher stomatitis, ocular surface events, and a low but meaningful ILD risk 23.
Histology-dependent efficacy in NSCLC is a critical clinical consideration: TROPION-Lung01 demonstrated superior outcomes in nonsquamous disease (PFS HR 0.63) but inferior outcomes in squamous histology (PFS HR 1.41), with statistical interaction confirmed (p=0.0006) 18. The EMA's December 2024 withdrawal of the Dato-DXd NSCLC application—citing insufficient efficacy robustness and ILD concerns—underscores the need for refined patient selection in this indication 26.
Biomarker strategies remain an active area of investigation. TROP2 expression by immunohistochemistry (IHC) has not emerged as a strict prerequisite for response with Dato-DXd, though TROP2-high subgroups showed amplified benefit in sacituzumab tirumotecan's TNBC trial (PFS 8.3 vs 2.3 months) 28. Factors including TROP2 internalization capacity, lysosomal protease activity, and tumor microenvironment composition are under investigation as refined predictive biomarkers.
Combination strategies are in active development: Dato-DXd plus pembrolizumab has been evaluated in first-line NSCLC (TROPION-Lung02), and phase III trials (TROPION-Lung14/15) will assess Dato-DXd ± osimertinib in EGFR-mutated NSCLC. Preclinical synergy with PARP inhibitors supports additional combination exploration in breast cancer 23.
5. Unmet Needs and Outlook
Despite meaningful progress, several challenges persist. Patient selection beyond binary TROP2 expression requires integrated biomarkers capturing internalization, trafficking, and stromal context. Resistance mechanisms—including TROP2 downregulation, upregulation of efflux pumps (BCRP, P-gp), and drug-tolerant persister (DTP) cell enrichment in EGFR-mutated NSCLC—have been identified in preclinical models but require prospective clinical validation 23. Optimal sequencing among TROP2 ADCs, other ADC classes (e.g., HER2-directed deruxtecan), and immunotherapy checkpoints remains undefined, and cross-ADC payload toxicity accumulation warrants systematic study.
Decentralized toxicity management—particularly for stomatitis, prolonged nausea, and early ILD detection—will be critical to preserving treatment intensity and patient quality of life as real-world use expands. The regulatory trajectory into 2026 suggests continued expansion: Dato-DXd now holds three FDA approvals 24252, sacituzumab tirumotecan holds NMPA Priority Review in NSCLC 30 with compelling phase III OS data 27, and China's broader pipeline—including ESG-401, SHR-A1921, DAC-002, and bispecific TROP2 ADCs (e.g., YH-012 targeting HER2/TROP2)—signals regional innovation beyond the established global leaders 23.
In summary, TROP2-directed ADCs have transformed the treatment landscape for multiple solid tumors, with distinct agents occupying complementary therapeutic niches shaped by ADC engineering, indication, and line of therapy. Continued investment in biomarker-driven selection, proactive safety management, and rational combination strategies will be essential to maximizing the clinical impact of this evolving drug class.